Hypodermic Needles Market Share

North America Market Insights

North America is projected to capture 34.8% of the global hypodermic needles market through 2036. The market growth is expected to be supported by its advanced healthcare infrastructure and high healthcare expenditure. The widespread adoption of injectable therapies also contributes to the increasing sales of hypodermic needles. Government-supported vaccination programs and seasonal immunization campaigns are further opening high-earning opportunities for hypodermic needle manufacturers.

The U.S. hypodermic needles market is estimated to reach USD 2,588.15 million by 2036. The country witnesses a consistent demand for hypodermic needles due to the growing prevalence of chronic diseases. The Centers for Disease Control and Prevention (CDC) estimates that in 2023, about 40.1 million people in the U.S. had diabetes, whether diagnosed or not. This was about 12.0% of the U.S. population. The expanding use of biologics, insulin, and specialty pharmaceuticals further strengthens the need for high-quality hypodermic needles.

Canada’s market for hypodermic needles is anticipated to expand at a CAGR of 6.52% from 2027 to 2036. The hypodermic needles market growth is supported by its publicly funded healthcare system and increasing chronic disease burden. The strong emphasis on patient safety drives the sales of hypodermic needles. As per the 2023 to 2024 data from the Canadian Chronic Disease Surveillance System, 8.2% of adults in Canada had diagnosed ischemic heart disease. The country's expanding elderly population and rising prevalence of cardiovascular diseases are increasing the demand for injectable solutions.

Asia Pacific Market Insights

Asia Pacific is estimated to hold 29.5% of the global hypodermic needles market through 2036. The market is expected to witness robust growth, driven by expanding healthcare infrastructure and a large and aging population. The increasing burden of chronic and infectious diseases is also contributing to the increasing sales of hypodermic needles. The government-led immunization programs and national vaccination initiatives also drive the trade in hypodermic needles.

China’s market for hypodermic needles was estimated at USD 425.50 million in 2026. The country’s vast population and expanding healthcare system are fueling the demand for hypodermic needles. The rapidly growing pharmaceutical industry is also contributing to the hypodermic needles market growth. The increasing prevalence of chronic diseases, including diabetes, hypertension, and cardiovascular disorders, is substantially increasing demand for hypodermic needles. The International Diabetes Federation reveals that the prevalence of diabetes in China is nearly 11.9%.

Japan is estimated to increase from USD 202.55 million in 2027 to USD 298.97 million by 2036. The high healthcare standards and swiftly increasing aging population are propelling the sales of hypodermic needles. The increasing prevalence of chronic diseases such as diabetes, cancer, osteoporosis, and cardiovascular disorders is boosting the trade of hypodermic needles. The Foundation for Promotion of Cancer Research reveals that Japan had an estimated 979,300 new cancer cases in 2024, including about 558,300 among men and 421,000 among women.

Japan's advanced healthcare systems are also contributing to the increasing sales of hypodermic needles. Technological innovations are set to fuel the adoption of premium disposable and safety-engineered hypodermic needles. The public-private hospital-led immunization programs and national vaccination initiatives are directly fueling the sales of hypodermic needles.

Cancer Case Statistics 2024

Source: Foundation for Promotion of Cancer Research

Europe Market Insights

Europe is projected to account for 25.9% of the global hypodermic needles by the end of the forecast period. The hypodermic needles market growth is supported by its well-established healthcare systems and growing demand for injectable therapies. The strong regulatory focus on patient and healthcare worker safety is also driving the sales of hypodermic needles. The increasing prevalence of chronic diseases is further boosting the application of hypodermic needles.

The Germany hypodermic needles market is estimated to be valued at USD 444.01 million by 2036. The country’s advanced healthcare infrastructure and strong medical device industry are propelling the sales of hypodermic needles. The rising surgical procedures and chronic disorders are fueling the application of hypodermic needles. Statistisches Bundesamt reports that there were 16,531,491 surgeries performed on fully admitted hospital patients in 2023.

The UK hypodermic needles market for hypodermic needles is set to expand at a CAGR of 5.38% during the forecast period. The increasing prevalence of chronic diseases and continuous investment in modern healthcare services are fueling the trade of hypodermic needles. The high volume of vaccinations and diagnostic procedures also contributes to the overall hypodermic needles market growth.